Dave Keng Boon Wee

Title: Dave Keng Boon Wee: Inventor in Biotechnology

Introduction

Dave Keng Boon Wee is an inventor based in Singapore. His work includes antisense oligonucleotides, which can be designed to influence gene expression and cellular activity. He is associated with 2 patents.

Latest Patents

One of Wee’s latest patents concerns antisense oligonucleotides for modulating T-cell function. The invention describes oligonucleotides that target RNA associated with immune-related molecules, including IFN-γ, granzyme, perforin 1, PD-1, and other targets. It also covers oligonucleotides that can induce RNA exon skipping and methods for further modifying T-cell specificity through a T-cell receptor gene.

Another patent relates to antisense oligonucleotides for modulating glycine decarboxylase (GLDC) activity. The invention describes exon-skipping approaches and includes pharmaceutical compositions, kits, and methods for treating cancer. It also outlines ways to assess GLDC levels or activity to help categorize cancer, determine prognosis, or inform treatment selection.

Career Highlights

Wee’s listed professional affiliations include the Agency for Science, Technology and Research and Lion Tcr Pte. Ltd. His patent work spans both immune-cell function and cancer-related research.

Collaborations

Among Wee’s listed coworkers are Bing Lim and Ernest Guccione. Their names provide context for the professional and research connections associated with his work.

Conclusion

Dave Keng Boon Wee’s patent portfolio reflects research into antisense oligonucleotides, T-cell function, and cancer, with applications ranging from exon skipping to potential therapeutic and diagnostic strategies.